Press release October 25th 2023
EUROAPI announces new governance
Chair of the Board Viviane Monges appointed Chief Executive Officer for an Interim period
- Karl Rotthier to step down as Chief Executive Officer, effective October 30, 2023
- Viviane Monges, Chair of EUROAPI’s Board of Directors appointed Chief Executive Officer for an interim period, effective October 30, 2023
- Elizabeth Bastoni appointed Independent Lead-Director
Paris – October 25, 2023 - EUROAPI’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer.
Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board.
In this context, the Board of Directors also decided to appoint Elizabeth Bastoni, Chair of the Nominations and Compensation Committee, as Independent Lead-Director. In this position, Elizabeth Bastoni will notably help to oversee the efficient running of the company’s governance structure and will be a key contact to engage with EUROAPI’s shareholders on topics related to the Board of Directors’ responsibilities.
The Board of Directors wants to thank Karl Rotthier for his contributions to EUROAPI since 2021, notably during EUROAPI’s early days, establishing the Company as a new independent major API and CDMO actor on the market.
The Board of Directors will continue to support the Group’s transformation in a fast-evolving environment and will actively oversee the execution of the strategic review announced on October 9, 2023.
Biography of Viviane Monges
Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, she held the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.
Biography of Elizabeth Bastoni
Elizabeth Bastoni is an experienced Board Chair and executive with expertise in human resources, governance, strategy, risk, and talent management. She is currently a member of the Board of Directors of Jeronimo Martins where she is on the Audit Committee. She is also on the Board of Directors of CNH Industrial where she Chairs the Human Capital and Compensation Committee. Elizabeth began her career in international taxation at KPMG in Europe. She then held several executive positions with international groups such as The Coca-Cola Company, Carlson or Thales.
Media Relations contact:
Tel.: +33 (0)6 81 86 80 19
Investor Relations contact:
Tel.: +33 (0)6 87 89 33 51
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.
Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.
Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group’s current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 “Risk factors” of the Universal Registration Document approved by the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 14, 2023, under number R.23-009 and the Amendment to Universal Registration Document approved by the AMF on April 25, 2023 under number R.23-015. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based.